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A B S T R A C T
BACKGROUND: Pleuroparenchymal ﬁbroelastosis (PPFE) has been described in hypersensitivity pneumonitis
(HP) yet its functional implications are unclear. Combined pulmonary ﬁbrosis and emphysema (CPFE) has oc-
casionally been described in never-smokers with HP, but epidemiological data regarding its prevalence is sparse.
CTs in a large HP cohort were therefore examined to identify the prevalence and eﬀects of PPFE and emphysema.
Methods: 233 HP patients had CT extents of interstitial lung disease (ILD) and emphysema quantiﬁed to the
nearest 5%. Lobar percentage pleural involvement of PPFE was quantiﬁed on a 4-point categorical scale:
0= absent, 1= aﬀecting<10%, 2= aﬀecting 10–33%, 3= aﬀecting> 33%. Marked PPFE reﬂected a total
lung score of ≥3/18. Results were evaluated against FVC, DLco and mortality.
RESULTS: Marked PPFE prevalence was 23% whilst 23% of never-smokers had emphysema. Following ad-
justment for patient age, gender, smoking status, and ILD and emphysema extents, marked PPFE independently
linked to reduced baseline FVC (p=0.0002) and DLco (p=0.002) and when examined alongside the same
covariates, independently linked to worsened survival (p=0.01).
CPFE in HP demonstrated a characteristic functional proﬁle of artiﬁcial lung volume preservation and dis-
proportionate DLco reduction. CPFE did not demonstrate a worsened outcome when compared to HP patients
without emphysema beyond that explained by CT extents of ILD and emphysema.
CONCLUSIONS: PPFE is not uncommon in HP, and is independently associated with impaired lung function and
increased mortality. Emphysema was identiﬁed in 23% of HP never-smokers. CPFE appears not to link to a
malignant microvascular phenotype as outcome is explained by ILD and emphysema extents.
1. Introduction
Over the past ﬁfteen years, the existence of idiopathic pleuropar-
enchymal ﬁbroelastosis (PPFE) has been increasingly recognised [1,2],
and in 2013, PPFE was included in the consensus classiﬁcation of the
idiopathic interstitial pneumonias [3]. However non-idiopathic PPFE
has been increasingly reported in association with several interstitial
lung diseases (ILD) including idiopathic pulmonary ﬁbrosis (IPF)
[2,4,5], hypersensitivity pneumonitis (HP) [2,6] and familial forms of
pulmonary ﬁbrosis [1,7]. As yet however, no large-scale CT study has
attempted to characterize the prevalence and associations of PPFE
occurring in tandem with an ILD.
Several recent studies have also identiﬁed the presence of emphy-
sema on CT imaging in never-smoker patients with rheumatoid ar-
thritis-related ILD (RA-ILD) [8,9], scleroderma-related ILD [10] and IPF
[11]. Reports also suggest that emphysema occurs in never-smoker
patients with HP [12–14]. Our study therefore aimed to characterize
the prevalence and functional and prognostic eﬀects of emphysema and
PPFE identiﬁed on CT imaging in a large population of patients with
hypersensitivity pneumonitis.
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2. Methods
2.1. Study population and clinical information
Patients with a multidisciplinary team diagnosis of HP, presenting
between January 2007 to July 2014 with volumetric non-contrast CT
examinations were identiﬁed. CT and pulmonary function protocols
have been previously described [15]. Approval for this study of clini-
cally indicated CT and pulmonary function data was obtained from the
Institutional Ethics Committee of the Royal Brompton Hospital.
The pulmonary function indices examined included forced ex-
piratory volume in the ﬁrst second (FEV1), forced vital capacity (FVC),
diﬀusing capacity for carbon monoxide (DLco), carbon monoxide
transfer coeﬃcient (Kco) and the composite physiological index (CPI)
[16].
2.2. Visual CT analysis
Each CT scan was evaluated independently by two radiologists (AO,
ALB) with 5 and 7 years thoracic imaging experience respectively,
blinded to all clinical information. Both scorers were given 15 non-
study cases to trial the scoring system and identify pre-existing biases.
The scores were reviewed with a third scorer (JJ) prior to the scoring of
the study cases.
Total interstitial lung disease extent was scored on a lobar basis (to
the nearest 5%), in six lobes, with the lingula and upper lobe char-
acterized separately in the left lung.
Three types of low attenuation lung, were quantiﬁed to the nearest
5% on a lobar basis and included expanded pulmonary lobules typical
of HP, cysts and emphysema.
The presence of pleuroparenchymal ﬁbroelastosis was identiﬁed on
a lobar basis (Fig. 1) using previously deﬁned CT criteria [2]. PPFE was
scored on a 4-point categorical scale as: 0= absent, 1=mild only af-
fecting< 10% of the pleural surface, 2=moderate aﬀecting 10–33%
of the pleural surface, 3= severe aﬀecting>33% of the pleural sur-
face. Arbitrated lobar PPFE scores were summed for each patient to
create an overall 19-point (potential scores of 0–18) scale for total
PPFE. Total PPFE scores were deﬁned as follows: trivial=≤2,
marked≥3.
Bronchial wall thickening and dilatation, which have been linked to
idiopathic PPFE [2] were evaluated on four-point categorical scales on
a lobar basis, using scoring systems previously used to estimate bron-
chial wall thickening and bronchiectasis severity [17–19]: bronchial
wall thickening: 0= absent, 1=mild, 2=moderate, 3= severe;
bronchial dilatation: 0= absent, 1= dilatation not reaching CT criteria
for bronchiectasis, 2=mild dilatation of 1–1.5 times the size of the
adjacent pulmonary artery, 3=marked dilatation of more than 1.5
times the size of the adjacent pulmonary artery. The presence/absence
of an obvious suprasternal depression was also noted (Fig. 1).
Finally the presence/absence of 4 CT features suggestive of non-
PPFE related pleural thickening were noted: 1= concentric smooth
pleural thickening extending over 15% of the area of a hemithorax and
lying distant to regions of PPFE, 2= calciﬁed pleural plaques consistent
with asbestos exposure, 3= ﬁbrocalciﬁc disease in the upper lobes
compatible with old tuberculous infection [20], 4= an apical cap,
characterized as a density centered on the lung apex, and extending
inferiorly (in the z-axis) as a continuous density for no more than 1 cm
[21].
2.3. Consensus formulation
Diﬀerences in ILD, airway and low attenuation scores between ob-
servers, were visualized by plotting the spread of diﬀerences in each of
the parenchymal pattern scores between observers. The graphs high-
lighted the variation in scores between observers for each individual CT
feature, but also allowed appreciation of cohort-wide systematic biases
held by each observer [15]. The most disparate 5% (2 SDs) of scores for
each CT pattern were arbitrated by a third scorer (JJ). Disparity in any
of the binary presence/absence scores was also arbitrated by the same
third scorer (JJ).
As PPFE is a relatively new sign, arbitration was performed by an
experienced radiologist with over 30 years of thoracic radiology prac-
tice (Professor David Hansell) to reduce the possibility of over-scoring
of PPFE. Any disparities in the designation of the presence/absence of
PPFE between scorers on a lobar basis, and any case in which the
maximum lobar PPFE extent identiﬁed by both scorers was< 10%
(mild PPFE), was arbitrated by the experienced radiologist.
2.4. Statistical analysis
Data are given as means with standard deviations, or numbers of
patients with percentages where appropriate. Interobserver variation
for visual scores was assessed using the single determination standard
deviation for continuous variables and the Kappa statistic for catego-
rical variables. PPFE group diﬀerences for categorical variables was
tested using the Kruskal Wallis test. Univariable and multivariable
linear regression analyses were undertaken to investigate relationships
between visual CT features and pulmonary function tests. Univariable
and multivariable Cox regression analyses were undertaken to in-
vestigate determinants of mortality. In all study analyses, a p-value
of< 0.05 was considered signiﬁcant. Linear regression models were
formally tested for heteroscedasticity to conﬁrm that the assumptions of
parametric analysis had been satisﬁed. Statistical analyses were per-
formed with STATA (version 12, StatCorp, College Station, TX, USA).
3. Results
3.1. Baseline data
The initial study population comprised 233 patients with a ﬁnal
multidisciplinary team diagnosis of HP based on a compatible clinical
history and review of the following data: antigen exposure history
(positive in 41% of patients), precipitating antibodies (identiﬁed in
35%), bronchoalveolar lavage ﬁndings (performed in 60%), CT imaging
(100%) and histopathology from lung biopsy (40%). No treatment in-
formation could be obtained for 7 patients. In the remaining patients
(n= 226), when considered on an intention to treat basis, 19/226 (8%)
patients were observed and not given steroids or immunosuppression
initially. 147/226 (65%) were initially treated with steroids alone. 21/
266 (9%) patients were treated with immunosuppression alone. 39/226
Abbreviations
CPFE combined pulmonary ﬁbrosis and emphysema
CPI composite physiological index
CT computed tomography
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(17%) were treated with both immunosuppression and steroids.
Demographic data, mean visual CT and pulmonary function tests
results are shown in Table 1. 3/233 (1%) patients were censored due to
incomplete follow-up, and the mean follow up time was 4.9 years.
Never-smoker patients had a total lifetime tobacco exposure of less than
100 cigarettes [22]. Interobserver variation scores for ILD and low at-
tenuation CT pattern extents are shown in Supplementary Table 1.
Observer agreement for the presence of PPFE (k=0.56) and for the
presence of emphysema (k= 0.44) was moderate (Supplementary
Table 2). Observer agreement improved with more extensive emphy-
sema extents (Supplementary Table 2).
3.2. Morphological/functional relations of PPFE
PPFE was identiﬁed in 93/233 (40%) patients and was trivial in 40/
233 (17%) and marked in 53/233 (23%). PPFE was never seen in any of
the middle or lower lobes without being present in both upper lobes. In
18/93 (19%) patients, PPFE was identiﬁed in the lower lobes without
being present in either middle lobe. Only 20 patients had surgical lung
biopsies (middle and lower lobes) performed or reviewed after 2012,
when PPFE was becoming better recognised as a clinical entity. Of these
20 patients, only 4 demonstrated marked PPFE on CT. Intra-alveolar
predominant ﬁbrosis was seen in 3/4 of the cases with marked PPFE,
with two of the cases demonstrating increased elastosis, in spite of the
fact that the biopsies obtained were distant to the location of the PPFE.
Regarding accessory PPFE features, a suprasternal depression was
seen in 23/233 (10%) study patients. 3/40 (8%) patients with trivial
PPFE and 20/53 (38%) patients with marked PPFE had a suprasternal
depression on CT (p=0.001). An apical cap was identiﬁed in 90/233
(39%) patients; which included 24/140 (17%) patients with no PPFE,
24/40 (60%) patients with trivial PPFE and 42/53 (79%) patients with
marked PPFE (p < 0.0001). Smooth pleural thickening distinct from
regions of PPFE (3/233 [1%] patients), granulomas suggestive of pre-
vious tuberculous infection (1/233 [<1%] patients) and pleural pla-
ques suggestive of previous asbestos exposure (6/233 [3%] patients)
were rarely seen in the study population.
No functional diﬀerence (FVC, DLco or CPI) was identiﬁed between
patients with no PPFE and patients with trivial PPFE, after adjusting for
covariates (patient age, gender, ILD and emphysema extent and
smoking status [never versus ever]). Consequently, in all further PPFE
analyses, patients with trivial and no PPFE were combined, and ex-
amined against patients with marked PPFE.
On univariate logistic regression, a positive smoking history was
negatively associated with marked PPFE (OR=0.36, 95%CI 0.18–0.76,
p=0.007). Marked PPFE was independently associated with a reduc-
tion in FVC and DLco following adjustment for covariates (patient age,
gender, ILD extent, smoking status [never versus ever] and emphysema
extent)[Table 2], with results maintained when examined selectively in
never-smoker HP patients (Supplementary Table 3).
3.3. Functional relationships of emphysema
Emphysema was seen in 70/233 (30%) HP patients, of which 37/88
(42%) patients were smokers and 33/142 (23%) were never-smokers
(Fig. 2). 11/33 (33%) never-smoker patients with HP had>5% em-
physema on CT. When examining all study patients with emphysema,
the mean emphysema extent was 7.2 ± 10.6%, with no signiﬁcant
diﬀerence seen in emphysema extent between smokers and never-
smokers (Supplementary Table 4). Emphysema in ex-smokers and
never-smokers was mostly a combination of centrilobular and para-
septal emphysema with a heavily upper lobe predominant distribution.
No statistical diﬀerence was seen in any low attenuation CT pattern
extent between smokers and never-smokers (Supplementary Table 4).
Patients with emphysema demonstrated preservation of lung vo-
lumes relative to patients without emphysema and similar mean DLco
values to patients without emphysema despite having less extensive ILD
Fig. 1. Axial CT images demonstrating a midline suprasternal depression which
was only ever seen in hypersensitivity pneumonitis patients with pleuropar-
enchymal ﬁbroelastosis (PPFE). The depression was invariably visible between
the clavicles, and was often accompanied by a concavity of the skin in the
midline of the back at the same level. Fig. 1a highlights dense pleural and
parenchymal aggregations of ﬁbrous tissue in a 71-year-old female never-
smoker exposed to avian antigens. Fig. 1b demonstrates PPFE in the left upper
lobe in a 59-year-old, male, never-smoker exposed to avian antigens and mould,
with a diagnosis of hypersensitivity pneumonitis conﬁrmed on surgical lung
biopsy. Fig. 1c demonstrates PPFE in the right upper lobe in a 43-year-old,
female, never-smoker with farmers lung, with a diagnosis of hypersensitivity
pneumonitis conﬁrmed on surgical lung biopsy.
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(Supplementary Table 5). Multivariable linear regression analyses were
performed to exclude a confounding eﬀect on functional indices from
covariates (age, gender, baseline ILD extent, smoking status and PPFE
severity [marked versus none/trivial]), and across all study patients,
emphysema extent demonstrated a CPFE functional phenotype with
preservation of lung volumes and a disproportionate reduction in DLco
(Table 2). In never-smokers, when using the same multivariable
models, emphysema extent was associated with obstructive functional
indices, and a disproportionate reduction in DLco, though preservation
of lung volumes did not reach statistical signiﬁcance (Supplementary
Table 3). When functional relationships were re-examined in patients
that had received treatment (n=207), 23% of the study population
with> 5% emphysema were excluded (as they were either managed by
observation or did not have treatment information available). As a re-
sult, whilst functional trends were maintained, underpowering resulted
in the independent FVC and DLco relationships with emphysema extent
not retaining signiﬁcance.
3.4. PPFE and emphysema mortality associations
On univariable Cox mortality analysis, emphysema presence, em-
physema extent and marked PPFE did not signiﬁcantly predict mor-
tality. In multivariable models adjusted for patient age, gender,
smoking status, ILD extent and PPFE (marked versus none/trivial),
marked PPFE independently predicted mortality (HR=1.97, 95%CI
1.16–3.33, p=0.01) unlike emphysema extent (Table 3).
When emphysema presence, representing the CPFE phenotype was
inserted into a Cox model containing patient age, gender, smoking
status, summed ILD and emphysema extent (representing the combined
morphological extent of parenchymal damage) and PPFE (marked
versus none/trivial), emphysema presence was not signiﬁcantly asso-
ciated with outcome (Table 3).
All multivariate Cox model ﬁndings were maintained when re-ex-
amined with adjustment for antigen exposure (identiﬁed antigen vs no
identiﬁed antigen) and in selective subanalyses of patients that received
treatment (steroids and/or immunosuppression – classiﬁed on an
Table 1
Patient age, gender and mean and standard deviations of pulmonary function indices and visually scored CT parameters in all patients with hypersensitivity
pneumonitis (Column 1), and subdivided according to patients with none/trivial PPFE and marked PPFE. Data represent mean values with standard deviations.
FEV1 = forced expiratory volume in the ﬁrst second, FVC = forced vital capacity, DLco = diﬀusing capacity for carbon monoxide, Kco = carbon monoxide transfer
coeﬃcient, CPI = composite physiological index, ILD = interstitial lung disease, PPFE = pleuroparenchymal ﬁbroelastosis.* = p < 0.001,
ˆ = p < 0.01,#=<0.05.
Variable (n= 233 unless stated) Entire Cohort None/trivial PPFE
(n= 180 unless stated)
Marked PPFE
(n= 53 unless stated)
Median Age (range) 62 (32–53) 63 (35–83) 56 (32–76)ˆ
Male/female 93/140 78/102 15/38#
Identiﬁable antigen (%) 41 45 49
Survival (alive/dead) 140/93 112/68 28/25
Never smokers/ever-smokers (n=230) 142/88 102/77 40/11ˆ
Pack years for smokers alone (n= 85) 17.9 ± 15.4 19.1 ± 15.7 (76) 7.6 ± 6.7 [9]
FEV1% predicted (n= 220) 68.2 ± 21.4 71.6 ± 21.2 (170) 56.3 ± 17.6 (50)*
FVC % predicted (n= 222) 69.8 ± 24.3 73.4 ± 24.5 (172) 57.5 ± 19.1 (50)*
FEV1/FVC % predicted (n= 220) 80.5 ± 9.2 79.9 ± 9.3 (170) 82.3 ± 8.6 (50)
DLco % predicted (n= 211) 41.8 ± 17.4 43.7 ± 18.1 (166) 34.9 ± 12.6 (45)*
Kco % predicted (n= 211) 70.6 ± 18.6 71.4 ± 19.2 (166) 67.7 ± 16.2 (45)
CPI (n= 208) 49.5 ± 16.4 47.7 ± 17.0 (164) 56.5 ± 11.8 (44)ˆ
CT scores (%)
Total ILD extent 47.6 ± 24.0 46.9 ± 25.2 49.7 ± 19.8
Mosaic attenuation 5.8 ± 7.4 5.8 ± 7.5 5.8 ± 7.0
Emphysema 2.2 ± 6.7 2.4 ± 7.4 1.5 ± 3.3
Cysts 0.5 ± 1.6 0.4 ± 1.4 0.7 ± 2.2
PPFE/airway scores (maximum score= 19)
PPFE extent (all patients) 1.6 ± 2.7 0.4 ± 0.7 5.5 ± 3.0*
PPFE extent (patients with PPFE only) 3.9 ± 3.0 3.9 ± 3.0 3.9 ± 3.0
Bronchial dilatation 0.6 ± 1.8 0.6 ± 1.7 0.8 ± 2.0
Bronchial wall thickening 5.2 ± 4.9 5.5 ± 4.8 4.2 ± 5.0
Table 2
Relationships between pulmonary function tests (FEV1/FVC ratio, FVC and DLco) and interstitial lung disease (ILD) and emphysema extents (measured as per-
centages), smoking status (never versus ever) and PPFE (marked versus none/trivial) in patients with hypersensitivity pneumonitis. All models were adjusted for
patient age and gender. FEV1= forced expiratory volume in the ﬁrst second, FVC= forced vital capacity, DLco=diﬀusing capacity for carbon monoxide,
PPFE= pleuroparenchymal ﬁbroelastosis.
Dependent variable CT variable Beta
Coeﬃcient
95% Conﬁdence Interval P value Model R value
FEV1/FVC ILD extent 0.09 0.05, 0.14 0.0001 0.47
Smoking status −1.68 −4.04, 0.68 0.18
Emphysema extent −0.45 −0.62, −0.28 < 0.0001
Marked PPFE 1.02 −1.79, 3.83 0.48
FVC ILD extent −0.50 −0.61, −0.39 < 0.0001 0.60
Smoking status 5.47 −0.13, 11.07 0.06
Emphysema extent 0.44 0.03, 0.84 0.03
Marked PPFE −12.67 −19.36, −5.98 0.0002
DLco ILD extent −0.39 −0.47, −0.31 < 0.0001 0.62
Smoking status 3.35 −0.72, 7.41 0.11
Emphysema extent −0.37 −0.66, −0.08 0.01
Marked PPFE −7.80 −12.75, −2.86 0.002
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intention to treat basis). All multivariate Cox model ﬁndings were also
maintained when PPFE severity and smoking status were omitted from
the models.
4. Discussion
Our study is the ﬁrst comprehensive examination of the prevalence
and impact of PPFE in HP patients. Marked PPFE was identiﬁed in 23%
of HP patients and was independently associated with a reduced FVC
and DLco, and, importantly, was independently predictive of mortality.
HP patients with emphysema demonstrated the typical CPFE proﬁle of
artiﬁcially preserved lung volumes with a disproportionate reduction in
DLco, and emphysema was identiﬁed in 23% of never smokers. We
have also demonstrated that HP patients with CPFE do not have a
worsened outcome compared to HP patients without emphysema, be-
yond that explained by CT extents of ILD and emphysema, a ﬁnding
which parallels outcome observations with regard to CPFE in patients
with IPF [11].
Previous studies of PPFE have relied on histological correlation of
imaging ﬁndings [2,4–6,23], and as a result have examined series with
limited patients numbers. Yet the CT appearances of PPFE are now well
described, having been included in the consensus statement for the
multidisciplinary classiﬁcation of the idiopathic interstitial pneumonias
[3]. Consequently, as per the study of Enomoto et al. [24], which ex-
amined CT appearances of patients with idiopathic PPFE, it is now
possible to interrogate large CT populations to determine the pre-
valence and functional and prognostic eﬀects of PPFE.
The well documented upper lobe predilection of PPFE [1,2,23,25]
was conﬁrmed in the current study, as PPFE was never found in a
Fig. 2. Axial CT image of the lungs demonstrating emphysema in never-smoker
patients with hypersensitivity pneumonitis. Fig. 2a and b demonstrate the
upper and lower lobes respectively of a 61-year-old male never-smoker who
kept birds and had avian and micropolysporia antibodies. Lucencies in keeping
with emphysema are visible throughout both lungs and demonstrate an upper
lobe predominance. Fig. 2c demonstrates the upper lobes of a 51-year-old fe-
male never-smoker with an unknown antigen exposure. Centrilobular lucencies
are visible in both upper lobes, but predominate in the right lung. Fig. 2d de-
monstrates the lung midzones in a 76-year-old male never-smoker, again with
no known antigen exposure. Centrilobular emphysematous foci are seen bilat-
erally, several of which contain a central vessel, with one lucency in the right
upper lobe surrounded by inﬂammatory ground glass density.
Table 3
Multivariable Cox regression models demonstrating mortality in HP patients
adjusted for patient age, gender, ILD and emphysema extents, smoking status
and pleuroparenchymal ﬁbroelastosis (PPFE) severity. The second model also
examined emphysema presence (representing the combined pulmonary ﬁbrosis
and emphysema phenotype). ILD=Interstitial lung disease.
Variable Hazard ratio
Adj(unadj)
95.0% Conﬁdence
Interval
P Value
Lower Upper
Age (years) 1·06 (1.05) 1·03 1·08 < 0.0001
Male Gender 1·19 (1.17) 0.75 1.88 0·46
Ever smoker 1.31 (1.31) 0.84 2.04 0.23
ILD extent (%) 1.02 (1.02) 1.01 1.03 < 0.0001
Emphysema extent (%) 1.02 (1.00) 0.98 1.05 0.33
PPFE (marked vs none/trivial) 1.94 (1.25) 1.15 3.27 0.01
Age (years) 1·06 (1.05) 1·03 1·08 < 0.0001
Male Gender 1·25 (1.17) 0.79 1.97 0·35
Ever smoker 1.38 (1.31) 0.88 2.15 0.16
Summed ILD and emphysema
extent (%)
1.02 (1.02) 1.01 1.03 < 0.0001
PPFE (marked vs none/trivial) 2.04 (1.25) 1.20 3.47 0.008
Emphysema presence 0.73 (0.90) 0.45 1.18 0.19
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middle or lower lobe without being evident in an upper lobe. Every
patient in the current series that demonstrated a suprasternal depres-
sion was found to have trivial or marked PPFE, indicating the strong
association of the CT sign with PPFE. A similar linkage has been pre-
viously noted between PPFE and a narrowed antero-posterior thoracic
diameter [4,26]. The presence of an apical cap was signiﬁcantly more
common when PPFE was marked, but demonstrated no relation to se-
quelae of previous tuberculous exposure.
A positive smoking history was found to protect against the devel-
opment of PPFE in the current study, conﬁrming previous observations
demonstrating idiopathic PPFE to be more common in non-smokers
[1,2,7,27–29]. The reasons for the apparent protective eﬀect of
smoking in PPFE are unclear. However, as PPFE can be conceptualized
as an expression of immune dysregulation, it is possible that loss of
vessels in the upper zone associated with smoking-related lung damage
may limit the development of PPFE on the visceral pleura.
The low baseline FVC identiﬁed in the current study is in line with
previous observations in idiopathic PPFE [23,24,29], however the
mean study DLco was lower than previous idiopathic PPFE reports
[23,24] which probably reﬂects the co-existent ﬁbrosis in our HP po-
pulation. Our observation that marked PPFE independently links to
mortality also conﬁrms observations in patients with idiopathic PPFE
who progressed with rapid declines in FVC [5,23,29].
With regard to our detailed emphysema evaluation, emphysema
across the entire study population was primarily centrilobular and
paraseptal in nature with an upper lobe predominant distribution. The
emphysema also demonstrated obstructive functional indices with a
CPFE functional proﬁle. The ﬁndings together suggest that parenchyma
labelled as emphysema is unlikely to have reﬂected misclassiﬁed hon-
eycombing. The aetiology of the emphysema identiﬁed in 23% of never
smokers cannot be veriﬁed but may reﬂect autoimmune [30] or in-
ﬂammatory parenchymal damage in a population where immune dys-
regulation is well recognised [31]. Proportions of never-smokers with
emphysema are also comparable to previous reports in IPF [11] and RA-
ILD [9]. The observation that HP patients with CPFE have no worsened
outcome that HP patients without emphysema once baseline extents of
ILD and emphysema have been considered also corroborates similar
ﬁndings in IPF [11] and RA-ILD [9].
There were limitations to the study. Firstly, the lack of compre-
hensive histopathological sampling to conﬁrm the presence of PPFE
might be seen as a major omission. However, given the detailed CT
descriptions of PPFE over the past 15 years, we believe that a PPFE
diagnosis can be made with conﬁdence without histopathological cor-
roboration. Furthermore, we aimed to quantify PPFE severity across the
entirety of the lungs, which would have been unachievable had we been
reliant on biopsy-based sampling. We also did not have histopatholo-
gical proof of an HP diagnosis. Yet in an era where surgical biopsies are
rarely performed in patients with ﬁbrosing lung disease, and guidelines
for the diagnosis of HP are awaited, reliance on a multidisciplinary
team diagnosis remains the gold standard, to which we adhered.
A further limitation related to the subanalysis of the independent
functional eﬀects of emphysema in HP patients receiving treatment.
Whilst trends of preserved lung volumes and DLco reduction were
maintained, the analyses were underpowered and did not retain sig-
niﬁcance. Corroboration that the functional trends in CPFE patients
identiﬁed in our study are independent of patient treatment, would best
be achieved through analyses of large multicentered patient popula-
tions. Lastly, the kappa values for interobserver agreement for the
presence of emphysema were moderate, but improved in patients with
more extensive emphysema extents. Arbitration of discrepant emphy-
sema scores primarily focused on patients with minor emphysema ex-
tents, and the adequacy of the consensus ﬁndings are reﬂected in the
good functional correlations of parenchyma classiﬁed as emphysema-
tous. Whilst better agreement for the presence of emphysema between
observers would be preferable, the ﬁndings in the current study are in
line with previous reports [9,11] and reﬂect the challenges inherent in
characterizing CT patterns, recognised throughout the ILD literature.
Regarding observer agreement for PPFE in the literature however, there
is limited information for patient cohorts of a comparable size to the
current study.
In conclusion, our study has demonstrated that in patients with HP,
marked PPFE, which is associated with reduced lung volumes and gas
transfer, is not uncommon and had a prevalence of 23% in our study
cohort. We have shown that HP patients with emphysema demonstrate
the characteristic lung function proﬁle of CPFE, and in our study cohort,
23% of never-smokers with HP demonstrated emphysema on CT ima-
ging. We demonstrate that CPFE in HP is not associated with a wor-
sened outcome, when compared to HP patients without emphysema,
once CT extents of emphysema and ILD have been considered.
However, marked PPFE does independently predict mortality in HP.
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